细胞因子反应性T细胞和NK细胞刻画多发性骨髓瘤患者的SARS-CoV-2疫苗应答与感染
研究对58例多发性骨髓瘤(MM)患者在SARS-CoV-2疫苗接种期间及突破性感染(BTI)后,采用全转录组与表面蛋白组单细胞联合分析及功能性血清学和T细胞验证。结果显示疫苗应答者细胞毒性CD4+ T细胞及表达FAS+/TIM3+的成熟CD38+ NK细胞显著过表达,并具强细胞因子反应性;发生BTI的MM患者产生强血清学和细胞应答,其细胞因子反应性免疫细胞模式与疫苗应答者相似。
要点
- 疫苗应答者中细胞毒性CD4+ T细胞和成熟CD38+ NK细胞(FAS+/TIM3+)显著过表达。
- 疫苗应答者具强细胞因子反应性,涉及I型干扰素、IL-12和TNF-α信号。
- 发生突破性感染的MM患者细胞因子反应性免疫细胞模式与疫苗应答者相似。
核心结论
- 疫苗应答者表现出细胞毒性CD4+ T细胞和成熟CD38+ NK细胞显著过表达,并具强细胞因子反应性。
- 发生突破性感染的多发性骨髓瘤患者产生强血清学和细胞应答,其细胞因子反应性免疫细胞模式与疫苗应答者相似。
- 本研究可拓展对免疫应答相关分子和细胞模式的理解,并可能有益于改进免疫缺陷患者的疫苗接种策略设计。
研究设计与样本
- 研究纳入58例多发性骨髓瘤患者,分析其外周血单个核细胞。
- 采用全转录组与表面蛋白组联合单细胞分析,并进行功能性血清学和T细胞验证。
- 分析时间点为SARS-CoV-2疫苗接种期间及突破性感染后。
主要发现
- 疫苗应答者中细胞毒性CD4+ T细胞和表达FAS+/TIM3+的成熟CD38+ NK细胞显著过表达。
- 疫苗应答者具强细胞因子反应性,涉及I型干扰素、IL-12和TNF-α介导的信号。
- 发生突破性感染的多发性骨髓瘤患者产生强血清学和细胞应答,其细胞因子反应性免疫细胞模式与疫苗应答者相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with multiple myeloma (MM) routinely receive mRNA-based vaccines to reduce COVID-19-related mortality. However, whether disease- and therapy-related alterations in immune cells and cytokine-responsiveness contribute to the observed heterogeneous vaccination responses is unclear. Thus, we analyzed peripheral blood mononuclear cells from patients with MM during and after SARS-CoV-2 vaccination and breakthrough infection (BTI) using combined whole-transcriptome and surface proteome single-cell profiling with functional serological and T-cell validation in 58 MM patients. Our results demonstrate that vaccine-responders showed a significant overrepresentation of cytotoxic CD4+ T- and mature CD38+ NK-cells expressing FAS+/TIM3+ with a robust cytokine-responsiveness, such as type-I-interferon-, IL-12- and TNF-α-mediated signaling. Patients with MM experiencing BTI developed strong serological and cellular responses and exhibited similar cytokine-responsive immune cell patterns as vaccine-responders. This study can expand our understanding of molecular and cellular patterns associated with immunization responses and may benefit the design of improved vaccination strategies in immunocompromised patients.
引用
- Enssle JC, Campe J, Moter A, et al. Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients. Leukemia. 2023. PMID: 38049509. doi:10.1038/s41375-023-02070-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。